Liquid biopsy is a non-invasive method, which can improve EML4-ALK translocation and ALK-TKIs resistance mechanisms detection, which will significantly improve ALK+ NCSCL diagnosis and patients management, leading to a better prognosis and quality of life of ALK+ NSCLC patients. Here, ALK is linked to non-small cell lung carcinoma.